A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients

Journal of Clinical Psychiatry

Volumn 58, Issue 4, 1997, Pages 146-152

  Kiev, Ari ^a   Feiger, Alan ^a  

^a Social Psychiatry Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CHLORAL HYDRATE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; PAROXETINE; SERTRALINE;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; IMPOTENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VERTIGO;

EID: 0030955543     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n0402     Document Type: Article

References (30)

1. Fuller RW, Wong DT. Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol 1987;7:14-20
2. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharmacy 1992;11:930-957
3. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-220
4. Conti L, Dell'osso L, Re F, et al. Fluvoxamine maleate: double-blind clinical trial vs placebo in hospitalized depressed patients. Curr Ther Res 1988; 43:468-480
5. Delgado PL, Price LH, Charney DS, et al. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988;11:55-60
6. Porro V, Fiorenzoni S, Menga C, et al. Single-blind comparison of the efficacy of fluvoxamine versus placebo in patients with depressive syndrome. Curr Ther Res 1988;43:621-629
7. Claasen V, Davies JE, Hertting G, et al. Fluvoxamine: a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol 1977;60:505-516
8. Claasen V. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol 1983;15(3, suppl):49S-55S
9. DeBree H, Van der School JB, Post LC. Fluvoxamine maleate: disposition in man. Eur J Drug Metab Pharmacokinet 1983;8:175-179
10. Luvox (fluvoxamine maleate). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997:2723
11. Nemeroff CB. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor. Pharmacotherapy 1994;14:127-138
12. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80(350, suppl):60-75
13. Tulloch IF, Johnson AM. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 1992;53(2, suppl):7-12
14. Wagner W, Zaborny BA, Gray TE. Fluvoxamine: a review of its safety profile in world-wide studies. Int J Clin Pharmacol 1994;9:223-227
15. Dunbar GC. An interim overview of the safety and tolerability of paroxetine. Acta Psychiatr Scand 1989;80(350, suppl):135-137
16. Wilde MI, Plosker GL, Benfield P. Fluvoxamine: an updated review of its pharmacology and therapeutic use in depressive illness. Drugs 1993;46: 895-924
17. Nemeroff CB. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol 1993;13(2, suppl):10S-17S
18. De Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Hosp Formul 1993;28:36-40
19. Kiev A. A double-blind, placebo-controlled study of paroxetine in depressed outpatients. J Clin Psychiatry 1992;53(2, suppl):27-29
20. Feigner JP, Boyer WF, Meredith CH, et al. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989;4:239-244
21. Shrivastava RK, Shrivastava SHP, Overweg N, et al. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. J Clin Psychiatry 1992;53(2, suppl):48-51
22. Wilson WH, Higano H, Papadatos Y, et al. A double-blind placebocontrolled study to compare the autonomie effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers. Br J Clin Pharmacol 1983;15:385S-392S
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987:245-247
24. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
25. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Dept Health, Education, and Welfare; 1976:337-340
26. COSTART. Coding Symbols for Thesaurus of Adverse Reaction Terms. Rockville, Md: US Dept Health, Education, and Welfare; 1989
27. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
28. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Science 1974; 19:1-15
29. Sussman N. The potential benefits of serotonin receptor-specific agents. J Clin Psychiatry 1994;55(2, suppl):45-51
30. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 1992;28:253-256